U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06887985) titled 'JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)' on March 19.
Brief Summary: This study is an investigator-initiated single center, single arm clinical study with a target population of patients with Refractory Autoimmune Diseases (ADs). It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of Refractory Autoimmune Diseases (ADs).
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Autoimmune Diseases
Intervention:
DRUG: JY231 Injection
This is an open-label, single-arm study to evaluate the efficacy and saf...